RNA
Income statement / Annual
Last year (2024), Avidity Biosciences, Inc.'s total revenue was $10.90 M,
an increase of 13.99% from the previous year.
In 2024, Avidity Biosciences, Inc.'s net income was -$322.30 M.
See Avidity Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$10.90 M |
$9.56 M |
$9.22 M |
$9.33 M |
$6.79 M |
$2.32 M |
$379.00 K |
| Cost of Revenue |
$0.00
|
$2.10 M
|
$1.39 M
|
$101.18 M
|
$37.60 M
|
$0.00
|
$8.44 M
|
| Gross Profit |
$10.90 M
|
$7.46 M
|
$7.84 M
|
-$91.86 M
|
-$30.82 M
|
$2.32 M
|
-$8.06 M
|
| Gross Profit Ratio |
1
|
0.78
|
0.85
|
-9.85
|
-4.54
|
1
|
-21.26
|
| Research and Development Expenses |
$303.59 M
|
$190.97 M
|
$150.40 M
|
$101.18 M
|
$37.60 M
|
$14.54 M
|
$8.44 M
|
| General & Administrative Expenses |
$86.24 M
|
$54.19 M
|
$37.73 M
|
$26.20 M
|
$13.46 M
|
$5.11 M
|
$2.44 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$86.24 M
|
$54.19 M
|
$37.73 M
|
$26.20 M
|
$13.46 M
|
$5.11 M
|
$2.44 M
|
| Other Expenses |
$0.00
|
-$2.10 M
|
-$1.39 M
|
-$101.18 M
|
-$37.60 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$389.83 M
|
$243.06 M
|
$186.75 M
|
$26.20 M
|
$13.46 M
|
$19.65 M
|
$10.88 M
|
| Cost And Expenses |
$389.83 M
|
$245.16 M
|
$188.14 M
|
$127.38 M
|
$51.06 M
|
$19.65 M
|
$10.88 M
|
| Interest Income |
$56.88 M
|
$23.97 M
|
$4.98 M
|
$104.00 K
|
$206.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$209.00 K
|
$7.39 M
|
$718.00 K
|
| Depreciation & Amortization |
$2.78 M
|
$2.10 M
|
$1.39 M
|
$639.00 K
|
$373.00 K
|
$348.00 K
|
$383.00 K
|
| EBITDA |
-$376.16 M |
-$233.50 M |
-$177.53 M |
-$117.41 M |
-$43.77 M |
-$17.00 M |
-$10.12 M |
| EBITDA Ratio |
-34.52
|
-24.42
|
-19.25
|
-12.59
|
-6.45
|
-7.33
|
-26.69
|
| Operating Income Ratio |
-34.77
|
-24.64
|
-19.4
|
-12.66
|
-6.52
|
-7.47
|
-27.7
|
| Total Other Income/Expenses Net |
$56.63 M
|
$23.38 M
|
$4.92 M
|
$42.00 K
|
-$78.00 K
|
-$7.40 M
|
-$718.00 K
|
| Income Before Tax |
-$322.30 M
|
-$212.22 M
|
-$174.00 M
|
-$118.01 M
|
-$44.36 M
|
-$24.73 M
|
-$11.22 M
|
| Income Before Tax Ratio |
-29.58
|
-22.2
|
-18.86
|
-12.65
|
-6.54
|
-10.67
|
-29.59
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$718.00 K
|
| Net Income |
-$322.30 M
|
-$212.22 M
|
-$174.00 M
|
-$118.01 M
|
-$44.36 M
|
-$24.73 M
|
-$11.93 M
|
| Net Income Ratio |
-29.58
|
-22.2
|
-18.86
|
-12.65
|
-6.54
|
-10.67
|
-31.49
|
| EPS |
-2.89 |
-2.91 |
-3.34 |
-2.85 |
-2.05 |
-0.86 |
-0.58 |
| EPS Diluted |
-2.89 |
-2.91 |
-3.34 |
-2.85 |
-2.05 |
-0.86 |
-0.58 |
| Weighted Average Shares Out |
$111.58 M
|
$73.01 M
|
$52.16 M
|
$41.43 M
|
$21.66 M
|
$37.51 M
|
$20.68 M
|
| Weighted Average Shares Out Diluted |
$111.58 M
|
$73.01 M
|
$52.16 M
|
$41.43 M
|
$21.66 M
|
$37.51 M
|
$20.68 M
|
| Link |
|
|
|
|
|
|
|
